Roche Glycart Ag

Hoffmann-la Roche Inc.

Engmab Sarl

Bristol-myers Squibb Compnay

Roche Glyeart Ag

Engmab Ag

F. Hoffmann-la Roche Ag

Engmab Beta Holdings LLC

Ralf Hosse

Ekkehard Moessner

Christian Klein

Pablo Umana

Anne Freimoser-Grundschober

Thomas U Hofer

Peter Bruenker

Marina Bacac

Oliver Ast

Valeria G Nicolini

Pablo Umaña

Inja Waldhauer

Samuel Moser

Guy Georges

Tanja Fauti

Klaus Strein

Wolfgang Schaefer

Claudia Ferrara Koller

Sandra Grau-Richards

Christiane Neumann

Tina Weinzierl

Juergen Michael Schanzer

Lydia Jasmin Hanisch

Stefan Seeber

Joerg Thomas Regula

Michael Molhoj

Werner Scheuer

Joerg Moelleken

Stefan Klostermann

Jens Fischer

Huisheng Wang

Maria Amann

Thomas Emrich

Christina Claus

Viktor Levitski

Claudio Sustmann

Kathryn Elizabeth Packman

Lei Shi

Peng Wang

Stefan Dengl

Rebecca Croasdale

Minh Diem Vu

Sylvia Herter

Wolfgang Richter

Alexander Knaupp

Halina Trochanowska

Laurence Bernard Peterson

Linda Wicker

Maximiliane Koenig

Barbara Weiser

Valeria Runza

Rebecca Croasdale-Wood

Huifeng Niu

Maria Valeria Gonzalez Nicolini

Sherif Daouti

Ningping Feng

Ramona Murr

Sabine Jung-Imhof

Lydia Jasmin Duerner

Daigen Xu

Johannes Sam

Katharina Wartha

Christiane Jaeger

Stephan Gasser

Jenny Tosca Thom

Cuiying Shao

Valerla G Nicolini

Michela Silacci-Melkko

Jean-Baptiste Vallier

Anne Freimoser-grundschober

Thomas Hofer

The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.

Anti-FAP antibodies and methods of use

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specific for OX40

The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to CD3 and CD19

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

T cell activating bispecific antigen binding molecules

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.

Bispecific antibodies against CD3EPSILON and ROR1

The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to NKG2D

The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific HER2 antibodies and methods of use

The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Bispecific antibody molecules binding to CD3 and TYRP-1

The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.

Tumor-targeted agonistic CD28 antigen binding molecules

The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Bispecific antibody molecules binding to CD3 and EGFRvIII

The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.

Interleukin-2 fusion proteins and uses thereof

The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Antibodies specific for DR5 and methods of use

Growing community of inventors

Cham, Switzerland

Ralf Hosse